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Local myonecrosis resulting from snakebite envenomation is not efficiently
neutralized by regular antivenom administration. This limitation is considered to
be a significant health problem by the World Health Organization. Phospho-
lipase A2-like (PLA2-like) proteins are among the most important proteins
related to the muscle damage resulting from several snake venoms. However,
despite their conserved tertiary structure compared with PLA2s, their biological
mechanism remains incompletely understood. Different oligomeric conforma-
tions and binding sites have been identified or proposed, leading to
contradictory data in the literature. In the last few years, a comprehensive
hypothesis has been proposed based on fatty-acid binding, allosteric changes
and the presence of two different interaction sites. In the present study, a
combination of techniques were used to fully understand the structural–
functional characteristics of the interaction between suramin and MjTX-II (a
PLA2-like toxin). In vitro neuromuscular studies were performed to characterize
the biological effects of the protein–ligand interaction and demonstrated that
suramin neutralizes the myotoxic activity of MjTX-II. The high-resolution
structure of the complex identified the toxin–ligand interaction sites. Calori-
metric assays showed two different binding events between the protein and the
inhibitor. It is demonstrated for the first time that the inhibitor binds to the
surface of the toxin, obstructing the sites involved in membrane docking and
disruption according to the proposed myotoxic mechanism. Furthermore,
higher-order oligomeric formation by interaction with interfacial suramins was
observed, which may also aid the inhibitory process. These results further
substantiate the current myotoxic mechanism and shed light on the search for
efficient inhibitors of the local myonecrosis phenomenon.
1. Introduction
Myonecrosis is an important local effect of envenomations
caused by snakebite accidents, which is not efficiently
neutralized by regular antivenom administration and may
evolve to permanent tissue loss, amputation and victim
disability (Lomonte et al., 2003; Otero et al., 2002). This toxic
manifestation is particularly serious in accidents involving
viperid snakes from the Bothrops genus, which are frequent
in Latin America (de Oliveira, 2009; Williams et al., 2010).
Myonecrosis results from the synergic action of different
venom components, including haemorrhagic metalloprotein-
ases that induce ischaemia and the myotoxic phospholipases
A2, which promote direct cytotoxicity towards skeletal muscle
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cells (Gutie´rrez et al., 2009). Phospholipases A2 (PLA2s; EC
3.1.1.4) comprise a large family of proteins that exhibit similar
tertiary structures and are widely found in snake venoms
(Dennis et al., 2011; Gutie´rrez & Lomonte, 2013). PLA2-like
proteins (or PLA2 homologues) comprise an important
subclass of these proteins that are often present in viperid
venoms, which are catalytically inactive because of a lack of
Ca2+ coordination related to natural mutations of the Asp49
and Tyr28 residues (Fernandes et al., 2010; Holland et al.,
1990). PLA2-like proteins, particularly Lys49-PLA2s (with an
Asp49Lys mutation), are intriguing proteins. They are small
proteins with conserved tertiary structure whose functions are
usually associated with oligomeric conformation changes and
different functional sites (Fernandes et al., 2014). Crystallo-
graphic, biophysical, biochemical and functional studies
aiming to understand the structural basis for myotoxic activity
have been performed, resulting in some consistent results and
interesting hypotheses (for a recent review, see Fernandes et
al., 2014). The most feasible and broad mechanism involves
the toxin in a particular dimeric conformation (known as an
‘alternative dimer’ or a ‘compact dimer’) that undergoes an
oligomeric change after fatty-acid binding, resulting in
membrane docking by a cationic site (MDoS) and ultimately
in membrane disruption by a hydrophobic site (MDiS;
Fernandes et al., 2013).
Structural experiments have been performed with complexes
formed of PLA2-like proteins and molecules that are poten-
tially capable of neutralizing their biological activities (de
Oliveira et al., 2003; Lomonte et al., 2009; Marcussi et al., 2007;
Murakami et al., 2005, 2007; Ticli et al., 2005). Some of these
molecules may also serve as models for the design of drugs
with anti-ophidian properties and therefore may also be
applicable as supplements to conventional serum therapy
(Marcussi et al., 2007). Suramin [8,80-{carbonylbis[imino-
3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonyl-
imino]}di(1,3,5-naphtalenetrisulfonic acid) hexasodium salt] is
one such compound because of its neutralizing properties
against the myotoxicity of Lys49-PLA2s (Arruda et al., 2002;
de Oliveira et al., 2003). This synthetic molecule is a highly
charged polysulfonated compound that has been used clini-
cally to treat African trypanosomiasis and onchocerciasis
(Burch & Ashburn, 1951; Cherry, 1960; Murakami et al., 2005;
Schneider, 1963; Williamson & Desowitz, 1956). When inves-
tigated with snake venoms, suramin was shown to inhibit the
neuromuscular blockade induced by pre-synaptic neurotoxins
such as crotoxin and -bungarotoxin (Fathi et al., 2011; Lin-
Shiau & Lin, 1999) and prevent the muscle necrosis promoted
by BthTX-I, a Lys49-PLA2 from B. jararacussu venom (de
Oliveira et al., 2003; Arruda et al., 2002).
We have recently performed structural and functional
studies of MjTX-II, a myotoxic Lys49-PLA2 from B. moojeni
(Salvador, Cavalcante et al., 2013). These experiments
revealed that this toxin presents structural peculiarities
compared with other Lys49-PLA2s that influence ligand
binding at the hydrophobic channel of the toxin. Furthermore,
we also demonstrated using myographic studies that MjTX-II
produces an irreversible and time-dependent blockage of
directly and indirectly evoked twitches, similar to other Lys49-
PLA2s (Cavalcante et al., 2005, 2007; de Oliveira et al., 2003;
Heluany et al., 1992; dos Santos, Cardoso et al., 2011; Gallacci
et al., 2006; Oshima-Franco et al., 2004; Randazzo-Moura et al.,
2008; Ponce-Soto et al., 2009; Rodrigues et al., 2004; Sta´beli et
al., 2006; Soares et al., 2001; Salvador, Fernandes et al., 2013).
In the present study, we explored the interaction of MjTX-
II and suramin using functional and structural approaches to
advance knowledge regarding the structural basis for the
mechanism of action of MjTX-II. A functional myographic
study on a mice phrenic diaphragm preparation was
performed to characterize the myotoxic effects of MjTX-II
and its neutralization by suramin. The high-resolution crystal
structure of the MjTX-II–suramin complex revealed inter-
action sites between the toxin and the ligand and its oligo-
meric conformation. Calorimetric assays were used to quantify
the interactions between the protein inhibitors, and finally
dynamic light-scattering and bioinformatics assays were
performed to further evaluate the oligomeric characteristics of
the complex.
2. Experimental procedures
2.1. Toxin isolation and suramin
MjTX-II was isolated from B. moojeni venom by ion-
exchange chromatography using a gradient of 0.05–0.5 mM
ammonium bicarbonate pH 8.0, as described previously
(Soares et al., 1998). Suramin sodium salt (catalogue No.
S2671) was obtained from Sigma–Aldrich, St Louis, Missouri,
USA.
2.2. Dynamic light scattering
Dynamic light-scattering (DLS) experiments were
performed with a protein concentration of 2.5 mg ml1 for
native MjTX-II and its complex with suramin (MjTX-II:
suramin molar ratio of 1:10) using a DynaPro Titan device
(Wyatt Technology) at 291 K. Measurements were performed
with the protein dissolved in 50 mM ammonium bicarbonate
pH 8.0, 50 mM sodium citrate pH 5.6. 100 measurements were
acquired in each experiment. Analysis of the final data was
performed with DYNAMICS v.6.10 (Wyatt Technology).
2.3. Isothermal titration calorimetry
MjTX-II–suramin isothermal titration calorimetric experi-
ments were performed with an iTC200 microcalorimeter
(MicroCal, GE Healthcare). Titrations were performed in
triplicate with the following general conditions: 2 ml injection
volumes, a 240 s time spacing between injections, a stirring
speed of 1000 rev min1, a reference differential power (DP)
of 5 mcal s1, 45 mM MjTX-II (in the reaction cell) and 600 mM
suramin (in the syringe). Assays were performed at 298 K in
50 mM ammonium bicarbonate buffer pH 8.0. Heats of dilu-
tion and mixing of suramin sodium salt were determined in
separate control experiments and were subtracted from the
titrations. Data analyses were performed using scripts based
on binding polynomials implemented in Origin (v.7.0;
research papers
Acta Cryst. (2015). D71, 2066–2078 Salvador et al.  Membrane docking and disruption sites on PLA2-like proteins 2067
OriginLab, Northampton, Massachusetts, USA) as described
previously (Freire et al., 2009; Zhou et al., 2008; Vega et al.,
2015).
2.4. Functional studies
In vitro neuromuscular studies were performed using a
myographic technique in order to verify the influence of
MjTX-II or its pre-incubation product with suramin upon the
contractile process of isolated phrenic nerve–diaphragm
muscle preparations of mice. Neuromuscular preparation has
proven to be an invaluable tool in the examination of snake
venoms and their components, since neuromuscular junctions
and muscle fibres are the main target of action of these
substances (for a review, see Hodgson & Wickramaratna,
2002). Diaphragm muscle can be stimulated either indirectly,
by brief pulses in the motor nerve, or directly on the muscle.
This allows discrimination between neurotoxic and myotoxic
effects of a snake venom or toxin (Harvey et al., 1994). While
neurotoxicity only causes the loss of the indirect twitches,
myotoxicity induces the depression of both direct and indirect
twitches (Harvey et al., 1994; Ownby et al., 1999).
Adult male mice (25–30 g) were sacrificed by exsanguina-
tion after cervical dislocation. The phrenic nerve–muscle
diaphragm preparations were removed and mounted verti-
cally in a conventional, isolated organ-bath chamber
containing 15 ml of a physiological solution with the following
composition: 135 mM NaCl, 5 mM KCl, 2 mM MgCl2, 15 mM
NaHCO3, 1 mM Na2HPO4, 11 mM glucose. This solution was
bubbled with carbogen (95%O2 and 5%CO2) and maintained
at 308  1 K. The preparation was attached to an isometric
force transducer (FT03, Grass Technologies) to record twitch
tensions. The transducer signal output was amplified and
recorded on a computer via a transducer signal conditioner
(Part No. 13-6615-50, Gould) with an AcquireLab Data
Acquisition System (Gould). The resting tension was 2 g.
Indirect contractions were evoked by supramaximal pulses
(0.2 Hz, 0.5 ms) delivered from an electronic stimulator
(S88K, Grass Technologies) and applied to the phrenic nerve
by means of a suction electrode. Direct contractions were
evoked by supramaximal pulses (0.2 Hz, 5 ms) through a
bipolar electrode positioned on opposite sides of the muscle.
The direct contraction experiments were performed in the
presence of pancuronium bromide (2 106 M). Preparations
were allowed to stabilize for 45 min before the addition of
MjTX-II (1 mM) or of a mixture of MjTX-II plus suramin
(10 mM) pre-incubated at 308 K for 15 min. Animal proce-
dures were in accordance with the guidelines for animal care
prepared by the Committee on Care and Use of Laboratory
Animal Resources, National Research Council, USA.
2.5. Crystallization and X-ray data collection
The purified MjTX-II fraction was concentrated to
10 mg ml1 in 0.05 mM ammonium bicarbonate pH 8.0 and
suramin solution was added to give a 1:8 molar ratio. Crystals
of the MjTX-II–suramin complex were obtained at 291 K from
a mixture of 1 ml protein–suramin solution and 1 ml reservoir
solution equilibrated against 500 ml reservoir solution
[30%(w/v) PEG 4000, 0.1 M Tris–HCl pH 8.5, 0.2 M lithium
sulfate] by the hanging-drop vapour-diffusion method
(Ducruix & Giege´, 1992).
X-ray diffraction data were collected from a single MjTX-
II–suramin crystal at a wavelength of 1.459 A˚ (at 100 K) using
a synchrotron-radiation source [MX2 station, Laborato´rio
Nacional de Luz Sincrotron (LNLS), Campinas, Brazil] and a
MAR CCD imaging-plate detector (MAR Research). The
crystal was mounted in a nylon loop and flash-cooled in a
stream of nitrogen at 100 K without cryoprotectant. A crystal-
to-detector distance of 100 mm and an oscillation range of 1
were used, resulting in the collection of 127 images. The data
were processed to 1.9 A˚ resolution using the HKL-2000
program package (Otwinowski & Minor, 1997).
2.6. Structure determination and refinement
The crystal structure of the MjTX-II–suramin complex was
solved by the molecular-replacement method using Phaser
(McCoy, 2007) from the PHENIX package v.1.8.4 (Adams et
al., 2010) using the coordinates of MjTX-II (PDB entry 4kf3;
Salvador, Cavalcante et al., 2013) as the search model. The
modelling process was performed by manual rebuilding using
Coot v.0.7.1 (Emsley & Cowtan, 2004). Polyethylene glycol
(PEG) 4000, water and suramin molecules were added by
Coot and refined using the PHENIX package v.1.8.4 (Adams
et al., 2010). Because of a lack of electron density, the amino-
acid side chains of Glu86 and Lys69 in monomer A and Lys128
in monomer B were not modelled. The PHENIX package and
MolProbity (http://molprobity.biochem.duke.edu/; Chen et al.,
2010) were used to check the general quality of the final
model. The coordinates were deposited in the PDB as entry
4yv5.
2.7. Comparative analysis
The structures of MjTX-II–suramin, MjTX-II (PDB entry
4kf3; Salvador, Cavalcante et al., 2013), BaspTX-II–suramin
(myotoxin II from B. asper venom; PDB entry 1y4l; Murakami
et al., 2005) and ecarpholin S–suramin (a myotoxic Ser49-
PLA2 from Echis carinatus venom; PDB entry 3bjw; Zhou et
al., 2008) were used. Molecular comparison of the structures
was performed using Coot v.0.7.1 (Emsley & Cowtan, 2004).
All structural figures were generated using PyMOL v.1.3
(Schro¨dinger).
2.8. Molecular-dynamics simulations
Molecular-dynamics (MD) simulations were performed
using GROMACS (Groningen Machine for Chemical Simu-
lation) v.4.5.3 (Van Der Spoel et al., 2005) for two experi-
mental conditions: four protomers of MjTX-II (a tetramer)
without ligands and four protomers of MjTX-II (a tetramer)
and four suramin molecules. The simulations were performed
using the protein models in the presence of explicit water
molecules. The GROMOS96 53a6 force field (Oostenbrink et
al., 2005) was selected to perform the MD simulations, and the
protonation states of the charged groups were set to a pH
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value of 7.0. The minimum distance between any atom of the
models and the box wall was 0.5 nm. Energy minimization
using a steepest-descent algorithm was performed to generate
the starting configurations of the systems. After this step,
200 ps of MD simulation with positional restraints applied to
the protein (PRMD) was executed to gently relax the systems.
50 ns of unrestrained MD simulation was then performed to
evaluate the stabilities of the structures. All MD simulations
were performed in a periodic truncated cubic box under
constant temperature (298 K) and pressure (100 kPa), which
were maintained by coupling to an isotropic pressure system
and an external heat bath (van Gunsteren & Berendsen,
1984). The suramin topology and coordinate files used in the
MD simulations were generated by the PRODRG2.5 server at
the University of Dundee (http://davapc1.bioch.dundee.ac.uk/
cgi-bin/prodrg).
The overall stereochemistry and fold quality of the protein
structural models obtained after initial modelling and MD
simulations were further examined with RAMPAGE (Lovell
et al., 2003) and ProSA-web (Wiederstein & Sippl, 2007). To
assess the quality of the MD simulations, the average root-
mean-square deviation/time graphs of the protein backbone
atoms were analyzed to examine the differences between the
total averages of two equal sets of points (the points corre-
sponding to the transient part of the simulations were not
considered).
3. Results
3.1. In vitro myotoxicity
MjTX-II at 1 mM promoted a time-dependent blockade of
both indirectly and directly evoked twitches in mouse neuro-
muscular preparations (Fig. 1). Pre-incubation with suramin
prevented approximately 85% of the muscle paralysis
promoted by MjTX-II, independent of whether the stimulus
was applied directly into the muscle or indirectly into the
nerve. Suramin alone did not alter muscle contractions
compared with the control.
3.2. Dynamic light scattering
DLS experiments were performed using the toxin dissolved
in ammonium bicarbonate pH 8.0 and sodium citrate pH 5.6.
An Rh value of 2.0 nm was obtained in both conditions, with
polydispersivity values of Pd = 9.5% at pH 5.6 and Pd = 13.9%
at pH 8. An average molecular weight of approximately
17 kDa was calculated considering MjTX-II to be a globular
protein (the sequence-based monomeric molecular weight is
13.887 kDa). A similar value was obtained (Rh = 2.3 A˚, Pd =
12%) for native MjTX-II dissolved in ultrapure water, as
described previously (Salvador, Cavalcante et al., 2013). These
results are also consistent with data obtained previously for
other Lys49-PLA2s (Fernandes et al., 2010). Thus, taking into
account that the structure is not perfectly globular, the data
suggest that native MjTX-II is predominantly dimeric, but the
presence of a fraction of the toxin in a monomeric confor-
mation may also be possible. Conversely, DLS measurements
of pre-incubated MjTX-II–suramin solution indicated protein
oligomerization (Rh = 4.2 nm, Pd = 13.7% at pH 5.6 and Rh =
3.5 nm, Pd = 14.5% at pH 8). The calculated molecular weight
of the complex is 98 and 63 kDa at pH 5.6 and 8.0, respectively.
These data clearly demonstrated the oligomerization process
undergone by the complex, and also suggest that the tetramer
is the predominant assembly for the complex at pH 8.0,
despite the relatively high polydispersivity value in these
measurements.
3.3. Interaction between MjTX-II and suramin
The interaction between MjTX-II and suramin was assessed
by ITC. A representative calorimetric titration is shown in
Fig. 2. The thermogram exhibited biphasic behaviour, indi-
cating at least two distinguishable binding events. To avoid a
priori constraints regarding the ligand-binding sites, a general
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Figure 1
Effects of MjTX-II and the product of its pre-incubation with suramin
on (a) directly and (b) indirectly evoked twitches in mouse phrenic
diaphragm preparations. The ordinate represents the percentage of
twitches relative to the initial amplitude. The abscissa indicates the time
(in minutes) after the addition of MjTX-II or a mixture of MjTX-II and
suramin to the organ bath. The data are grouped as means  standard
error of the mean (P < 0.05). The asterisk indicates the point after which
there was a significant difference compared with the control.
model with two binding sites based on the overall association
constants (1 and 2) and binding enthalpies (H1 and H2)
was employed. Nonlinear regression analysis allowed the
estimation of binding parameters (Table 1). An interaction
constant  (= 42/1
2) of 0.1 and a Hill coefficient of 0.5 indi-
cated that the binding sites are either non-identical or iden-
tical exhibiting negative cooperativity.
Intrinsic site-specific binding parameters were calculated
from the overall association parameters: the dissociation
constants for the binding of the first and second events and
their corresponding binding enthalpies (Table 1). The first
binding event presented a dissociation constant of 0.6 mM,
whereas the second binding event displayed a dissociation
constant of 6.2 mM (a tenfold reduction in binding affinity).
There was a considerable difference in the binding enthalpies:
the first event exhibited unfavourable enthalpy (entropically
driven), whereas the second event exhibited favourable
enthalpy (enthalpically driven, with a 23.4 kcal mol1
difference in enthalpy).
3.4. Crystallographic structure of the MjTX-II–suramin
complex
The MjTX-II–suramin crystals belonged to space group
P212121 and diffracted to 1.9 A˚ resolution. The refinement
converged to an Rcryst value of 19.7% (Rfree = 22.8%) with a
final model (Fig. 3a) composed of 197 solvent molecules, two
suramin molecules (Fig. 3b), seven sulfate ions and three
polyethylene glycol 4000 (PEG 4K) molecules. This model
revealed two protomers (identified as A and B) in the asym-
metric unit. The refinement statistics and other information
are provided in Table 2. Suramin molecules bind to both
monomers of the MjTX-II–suramin complex in a symmetric
manner, establishing interactions with both the C- and
N-termini of the toxin (the Lys7, Leu10, Asn114, Lys116,
Tyr119, Tyr121, Leu122 and Phe126 residues are involved in
these interactions; Figs. 4a and 4b).
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Table 1
Thermodynamic values for the binding of suramin to MjTX-II.
kd1 and kd2 are the intrinsic dissociation constants for the binding of the first
and second ligand. h1 and h2 are the intrinsic binding enthalpies for the
binding of the first and second ligand. 1 and 2 are the overall association
constants for the first and second binding events.H1 andH2 are the overall
binding enthalpies for the first and second binding events.  is the interaction
cooperativity constant (= 42/1
2).h is the interaction cooperativity enthalpy.
nH is the Hill coefficient [= 2/(1 + 
1/2)].
Dissociation binding constants and binding enthalpies
kd1 (mM) 0.6  0.1
h1 (kcal mol
1) 5.2  0.2
kd2 (mM) 6.2  1.2
h2 (kcal mol
1) 18.2  0.6
Overall binding parameters determined by nonlinear regression
1 (M
1) (3.1  0.5)  106
H1 (kcal mol
1) 5.2  0.3
2 (M
2) (2.5  0.4)  1011
H2 (kcal mol
1) 13.0  0.3
 0.10  0.03
h (kcal mol1) 23.4  0.4
nH 0.5  0.2
Figure 2
Calorimetric titration of suramin sodium salt into MjTX-II. The upper
panel shows the raw data thermogram (thermal power as a function of
time) of the titration of MjTX-II (200 ml, 45 mM) with 600 mM suramin
sodium salt. The lower panel shows the binding isotherm (ligand-
normalized integrated heat as a function of the molar ratio). Affinities
and enthalpy changes were determined by a general nonlinear regression
model considering two ligand-binding sites (solid line).
Table 2
X-ray data-collection and refinement statistics.
Values in parentheses are for the highest resolution shell.
Unit-cell parameters (A˚) a = 50.8, b = 63.6, c = 87.7
Space group P212121
Resolution (A˚) 31.82–1.90 (1.96–1.90)
Unique reflections 23031 (2258)
Completeness (%) 99.9 (99.7)
hI/(I)i 8.6 (2.5)
Multiplicity 4.9 (4.7)
Molecules in asymmetric unit 2
Rmerge† (%) 14.4 (78.9)
Rcryst (%) 19.7
Rfree (%) 22.8
No. of non-H atoms
Protein 1916
Waters 197
Suramin molecules 2
PEG 4K molecules 3
Sulfate ions 7
Wilson B factor (A˚2) 20.6
Ramachandran plot‡ (%)
Favoured 95.0
Outliers 0.91
† Rmerge =
P
hkl
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ, where Ii(hkl) is the intensity of
an individual measurement of the reflection with Miller indices hkl and hI(hkl)i is the
mean intensity of that reflection. Calculated for I > 3(I). ‡ Calculated with
MolProbity (Chen et al., 2010).
The crystallographic structure of MjTX-II complexed with
suramin presents a similar fold to other class II PLA2s, is
stabilized by seven disulfide bridges and is composed of the
following secondary-structure elements: an N-terminal -helix
(h1), a ‘short’ helix, a Ca2+-binding loop, two antiparallel
-helices (h2 and h3), two short strands of antiparallel
-sheets (known as -wings) and a C-terminal loop (Arni &
Ward, 1996; Magro et al., 2009). The MjTX-II–suramin struc-
ture, like other PLA2-like structures, presents a hydrophobic
channel which links the protein surface to its putative active
site. This cleft is present for both catalytic PLA2s and PLA2-
like proteins, displaying conserved residues (e.g. His48) that
are fundamental for the catalytic process (in PLA2s; Scott &
Sigler, 1994) or for the mechanism of toxicity (in PLA2-like
proteins; dos Santos et al., 2009).
The majority of PLA2-like toxins present dimeric arrange-
ments in their crystals and in solution (Fernandes et al., 2014).
Additionally, the unit-cell packing of MjTX-II–suramin and
most Lys49-PLA2 structures presents two possible dimeric
configurations: (i) the ‘alternative dimer’ or ‘compact dimer’
and (ii) the ‘conventional dimer’ or ‘larger dimer’. This issue
has been extensively analyzed in different studies, with the
‘alternative dimer’ being the most likely conformation to
occur in solution (for a review, see Fernandes et al., 2014).
Inspection of the MjTX-II–suramin unit-cell packing using
PISA (Krissinel & Henrick, 2007) also suggested that the
‘alternative dimer’ conformation is the most probable
conformation to occur in solution: the ‘alternative dimer’ had
a complexation signification score (CSS) of 0.2, an interfacial
area of 512.5 A˚2 and iG = 9.4 kcal mol1, while the
‘conventional dimer’ had a CSS of 0, an interfacial area of
348.2 A˚2 and iG = 0.2 kcal mol1. Thus, the first assembly
(alternative dimer) was selected for the MjTX-II–suramin
structure and used in refinement.
The particular mode of suramin
binding on the toxin surface, in which
there is a ligand on each side of the
dimer (Fig. 3a), enables other toxin
dimers to interact with each side of the
complex, allowing higher-order complex
formation (Fig. 3c). Notably, this oligo-
meric organization of the MjTX-II–
suramin complex is composed of four
protomers that are composed of two
dimers in the ‘alternative dimer’
conformation (from two asymmetric
units) related by a twofold axis. The
majority of the contacts between the
dimers are between two suramin mole-
cules that are located in the dimeric
interface (Fig. 3c). Further analyses with
PISA (using the protomers, suramin and
the interfacial PEG 4K molecules)
suggested a tetrameric conformation as
a stable assembly in solution. Another
interesting feature that is observed in
the tetrameric arrangement is the
presence of both ‘alternative’ and
‘conventional’ dimers (Fig. 3c). Thus,
despite the ‘alternative’ conformation
being more favourable in solution for
most Lys49-PLA2s, the ‘conventional’
conformation is found in the case of a
tetrameric arrangement, such as in
MjTX-II–suramin and MjTX-I
(Salvador, Fernandes et al., 2013).
3.5. Comparison between MjTX-II and
the MjTX-II–suramin complex
MjTX-II and the MjTX-II–suramin
complex displayed similar dimeric
structures (r.m.s.d. of 0.33 A˚). The main
differences between these structural
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Figure 3
Crystal structure of the MjTX-II–suramin complex. (a) The overall structure of the MjTX-II–
suramin complex is depicted as a ribbon diagram. Suramin molecules (yellow) are illustrated as stick
representations. The electron-density map (coefficients |Fobs|  |Fcalc|) of the MjTX-II–suramin
complex is shown in the area corresponding to the ligand and is contoured at 1.0. (b) Tetrameric
configuration of the MjTX-II–suramin complex formed by two dimers in the asymmetric unit. This
oligomeric conformation was suggested by PISA (Krissinel & Henrick, 2007), dynamic light
scattering and molecular-dynamics simulations to be stable in solution. Both ‘alternative’ and
‘conventional’ dimers were observed in this oligomeric conformation (Fernandes et al., 2014).
models are observed in the ligand-binding regions (Figs. 5b
and 5d). The MjTX-II structure contains four PEG 4K
molecules: the PEG 4K(1) and PEG 4K(2) molecules inside
the hydrophobic channel of each dimer, PEG 4K(3) inter-
acting with the Lys7 region and PEG 4K(4) interacting with
the hydrophobic channels of both monomers simultaneously
(each tail is bound to each monomer). In the MjTX-II–
suramin complex there are only three PEG 4K molecules [the
PEG 4K(4) molecule is absent]. Additionally, the PEG 4K(3)
molecule observed in the vicinity of the Lys7 residue presents
a different configuration compared with that observed in the
MjTX-II structure. Part of this PEG 4K molecule interacts
with one of the monomers of the adjacent dimer of the
asymmetric unit of the MjTX-II–suramin structure (Fig. 3a).
Finally, the most important characteristic of the complex is the
presence of two suramin molecules on the surface of the toxin
dimer. This particular binding mode of the ligands on the
protein surface creates the possibility of the occurrence of a
high-order oligomeric assembly.
3.6. Comparison between PLA2-like toxins complexed with
suramin
Three structures of PLA2-like toxins complexed with
suramin have been solved: (i) MjTX-II–suramin (this work),
(ii) BaspTX-II–suramin (a Lys49-PLA2 from B. asper; Mura-
kami et al., 2005) and (iii) ecarpholin S–suramin (a Ser49-
PLA2 from E. carinatus; Zhou et al., 2008). Notably, the ligand
binds to different parts of each protein, leading to different
oligomeric conformations of the toxins.
A comparison between the crystal structures of the two
Lys49-PLA2s complexed with suramin (MjTX-II–suramin and
BaspTX-II–suramin) in their dimeric arrangement is shown in
Fig. 5(a). The structure of the BaspTX-II–suramin complex
demonstrated that suramin interacts with the putative
calcium-binding loop and C-terminal regions. The ligand is
bound at the entrance to the hydrophobic channel of the toxin,
blocking the access to a possible activator molecule (see x4.3).
In MjTX-II–suramin, by contrast, the inhibitor is bound at the
external portion of the protein in both monomers (Fig. 3a)
by several hydrophobic contacts and three polar contacts
(Figs. 4a and 4b). This particular mode of interaction also
results in oligomerization of the complex, mainly by contacts
between the suramin molecules. The reasons for the ligand-
binding differences between these two proteins arise from two
unique sequence features of MjTX-II compared with all other
Lys49-PLA2s (Salvador, Cavalcante et al., 2013): (i) a mutation
in the putative Ca2+-binding loop (Leu32Gly) causes the
binding of the additional PEG 4K(4) molecule (Fig. 5d) in the
structure of MjTX-II–PEG 4K and of an additional fatty-acid
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Figure 4
Interaction of suramin molecules in the MjTX-II structure. (a) and (b) represent the interactions of suramin 1 and suramin 2 bound to monomers A and
B of MjTX-II, respectively. Polar contacts are depicted as broken lines and hydrophobic contacts are indicated by arcs with radiating spokes. This figure
was drawn using LIGPLOT (Wallace et al., 1995).
molecule in the structure of MjTX-II–stearic acid (Watanabe
et al., 2005) and (ii) an insertion in the MjTX-II C-terminus
(Asn120) also confers a different conformation to this region,
leading to the binding of the additional PEG 4K(3) (Fig. 5d) in
the MjTX-II–PEG 4K structure or a fatty-acid molecule in the
MjTX-II–stearic acid structure (Salvador, Cavalcante et al.,
2013; Watanabe et al., 2005). Indeed, phylogenetic studies with
PLA2-like toxins demonstrated that the MjTX-II sequence is
in an isolated and primitive branch of the Lys49-PLA2 clade
(dos Santos, Cintra-Francischinelli et al., 2011; Salvador,
Fernandes et al., 2013).
A superposition of the MjTX-II–suramin and ecarpholin S–
suramin (Zhou et al., 2008) dimers is shown in Fig. 6. It can be
observed that although they present a conserved secondary
structure, their oligomeric structures are very different and the
C-terminal regions also display different conformations.
The ecarpholin S–suramin crystal structure contained three
suramin ligands interacting with different portions of
C-terminal and N-terminal regions of the toxin mainly by
polar contacts. Interestingly, despite structural and sequential
differences between the toxins (MjTX-II and ecarpholin S),
some parts of the suramin ligands bind to similar regions (the
C-terminal and N-terminal portions), and interaction between
the ligands resulted in the oligomerization of both proteins.
3.7. Molecular-dynamics studies
MD simulations were performed to check the stability of
the tetrameric structure of the complex observed in the unit
cell. Thus, two different models were used for the MD simu-
research papers
Acta Cryst. (2015). D71, 2066–2078 Salvador et al.  Membrane docking and disruption sites on PLA2-like proteins 2073
Figure 5
Structural comparison between the dimeric MjTX-II–suramin complex structure and other Lys49-PLA2 structures. (a) Superposition of the MjTX-II–
suramin (ribbon diagram in black and suramin molecules in yellow) and BaspTX-II–suramin (ribbon diagram in grey and suramin molecules in magenta)
structures. (b) Cartoon representation of the dimeric MjTX-II–suramin complex structure (black); the three PEG 4K molecules and two suramin
molexules are shown in green and yellow, respectively. (c) Cartoon representation of the BaspTX-II–suramin complex structure (grey); the two PEG 4K
molecules are shown in green and the two suramin molecules are shown in magenta. (d) Cartoon representation of the MjTX-II structure (grey) with its
four PEG 4K molecules shown in green.
lations: (i) a crystallographic tetrameric assembly of the
complex (four protomers and four interfacial suramin mole-
cules, named the bound assembly) and (ii) a crystallographic
tetrameric assembly without suramin ligands (four protomers,
named the unbound assembly).
The simulations showed that the bound assembly had a
lower average r.m.s.d. value and also a lower level of r.m.s.d.
fluctuations compared with the unbound assembly (Fig. 7).
Thus, these data showed that the bound tetrameric assembly
presented a lower tendency for movement between the dimers
along the tetrameric interface, indicating tight interactions
between the suramin molecules and toxin protomers.
4. Discussion
4.1. Myotoxic activity of MjTX-II is neutralized by suramin
Functional myographic studies performed on isolated
neuromuscular preparations are suitable for screening the
neurotoxic and myotoxic components of snake venoms
(Gallacci & Cavalcante, 2010; Harvey et al., 1994; Ownby et al.,
1999). Although neurotoxic activity is characterized by the
exclusive blockade of indirect contractions, myotoxicity causes
a loss of both direct and indirect twitches (Ownby et al., 1999).
The present study demonstrates that MjTX-II, similar to other
Lys49-PLA2s, induces a blockade of both indirect and direct
twitches in mouse phrenic diaphragm preparations (Caval-
cante et al., 2005; de Oliveira et al., 2003; Gallacci et al., 2006;
Heluany et al., 1992; Oshima-Franco et al., 2004; Ponce-Soto et
al., 2009; Randazzo-Moura et al., 2008; Rodrigues et al., 2004;
Salvador, Fernandes et al., 2013; Salvador, Cavalcante et al.,
2013; Soares et al., 2001; Sta´beli et al., 2006). The muscle
paralysis induced by myotoxic PLA2s has been attributed to
muscle-fibre unexcitability consequent to prolonged depolar-
ization resulting from the alteration of cell-membrane
permeability. Even though morphological studies clearly
demonstrate that Lys49-PLA2s can induce muscle damage,
functional myographic approaches reveal the early stages of
this toxic effect (de Oliveira et al., 2003; Cavalcante et al., 2007;
dos Santos, Cardoso et al., 2011).
As described above, pre-incubation with suramin neutra-
lizes the muscle paralysis promoted by MjTX-II in mouse
phrenic nerve–diaphragm preparations, regardless of whether
the stimulus was applied indirectly on the nerve or directly
on the muscle. Thus, based on the above considerations, we
suggest that suramin neutralizes the myotoxic effect of MjTX-
II. Similar findings regarding the antimyotoxic effect of
suramin have previously been described against other PLA2-
like proteins, such as Lys49-PLA2s [BthTX-I from B. jarar-
acussu (de Oliveira et al., 2003), BaspTX-II (Murakami et al.,
2005)] and ecarpholin S (Zhou et al., 2008).
The mechanism of action of suramin at the neuromuscular
junction remains unclear, but it is known that suramin
blockades presynaptic voltage-dependent Ca2+channels on the
motor nerve terminal, reducing the release of acetylcholine
(Henning et al., 1996; Lin et al., 2000). However, this mode of
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Figure 6
Superposition of the dimeric MjTX-II–suramin and the Ser49-PLA2 escarpholin S–suramin structures. (a) Cartoon representation of the MjTX-II–
suramin (green) and escarpholin S–suramin (light brown) structures. (b) The same superposition as in (a) but including the suramin molecules. One
monomer of each structure was superposed to illustrate the oligomeric differences between the complexes.
action cannot account for the inhibitory effect of suramin on
muscle paralysis induced by MjTX-II and other PLA2-like
toxins. Indeed, these functional results also corroborate our
crystallographic and calorimetric assay results, indicating that
suramin can interact with MjTX-II with high affinity and form
complexes that are inactive.
4.2. Oligomerization of the MjTX-II–suramin complex
Most apo and complexed PLA2-like structures are dimeric,
as demonstrated by crystallography, DLS, SAXS and size-
exclusion chromatography, among other techniques (Mura-
kami et al., 2007; dos Santos et al., 2009; Fernandes et al., 2010,
2014). In particular, the crystal structure of MjTX-II was also
solved as a dimer (de Azevedo et al., 1997; Watanabe et al.,
2005; Salvador, Cavalcante et al., 2013). The MjTX-II–suramin
structure also presents a dimeric conformation in its asym-
metric unit; however, analysis of its unit cell shows that owing
to crystallographic symmetry the tetrameric conformation
seems to be most likely to occur. Notably, the dimeric
conformation observed in the MjTX-II structure is also
preserved in the MjTX-II–suramin structure. However,
because the ligand binds on the surface of the toxin, a tetra-
meric arrangement formed by two dimers occurs in the unit
cell.
To test whether the tetrameric arrangement occurs in
solution, we also performed other experiments which, despite
the particularities and limitations of each technique, demon-
strated that a high-order oligomeric conformation is feasible.
MD simulations demonstrated that the tetrameric conforma-
tion is more stable in the presence of the ligand. DLS assays
indicated that the presence of the ligand induces the formation
of higher-order oligomers, and also suggested that the tetra-
meric assembly is predominant at pH 8. ITC experiments
indicated two binding events characterized by dissociation
constants in the low micromolar range with a tenfold differ-
ence. Thus, these two events may be attributed to binding of
suramin to the surface of MjTX-II (the first event with a
higher dissociation constant, with positive enthalpy and
entropically driven) and the interaction between the two
dimers (by suramin and -sheet residues) forming the tetra-
meric arrangement (the second event with a lower dissociation
constant and enthalpically driven).
Suramin-induced oligomerization has also been reported
for ecarpholin S, a Ser49-PLA2 from E. carinatus venom
(Zhou et al., 2008). The myotoxic activity of ecarpholin S is
significantly inhibited by suramin, and oligomerization may be
essential for this inhibition: the apo form of this protein
changed from a monomeric to a dimeric state (in the asym-
metric unit) and an octameric conformation (in the unit cell)
when in the presence of suramin (Zhou et al., 2008). Thus,
considering the crystallographic and biophysical experiments,
in which we showed that the oligomerization process also
occurs for MjTX-II, we suggest that this phenomenon may
also play an important role in the mechanism of inhibition of
PLA2-like toxins by suramin.
4.3. Structural basis for the inhibition of MjTX-II by suramin
The mechanism of action of Lys49-PLA2s upon muscle
fibres has been much discussed over the last several years, and
great progress has been achieved regarding this topic. It is
already known that Lys49-PLA2s act as dimers through their
C-terminal region (Chioato et al., 2002; Ward et al., 2002). It
has been proposed that C-terminal (Lys115 and Arg118) and
other basic residues (such as Lys20) are the main residues
responsible for membrane anchorage (dos Santos et al., 2009).
More recently, this anchorage site was named the membrane-
docking site (MDoS) and other functional sites responsible
for membrane disruption (called membrane-disruption sites;
MDiS) consisting of the C-terminal hydrophobic residues
(Leu121 and Phe125 in Lys49-PLA2s and Leu122 and Phe126
in MjTX-II because of a residue insertion) have been identi-
fied (Fernandes et al., 2013). Thus, a myotoxic mechanism
composed of five steps was proposed: (i) fatty-acid binding at
the hydrophobic channel of the toxin, (ii) allosteric activation,
(iii) protein–membrane docking (MDoS), (iv) protein pene-
tration and disruption (MDiS) and (v) cell death (Fernandes et
al., 2013).
Based on the available structural and functional data,
different ‘classes’ of inhibitors of PLA2-like proteins have
been proposed: (i) ligands that bind in the hydrophobic
channel (e.g. p-bromophenacyl bromide; BPB), (ii) ligands
that block or restrict access to the hydrophobic channel (e.g.
rosmarinic acid) and (iii) ligands that bind to the C-terminus
or the MDoS (dos Santos et al., 2009; Fernandes et al., 2014).
Notably, the crystal structure of the MjTX-II–suramin
complex shows that suramin binds simultaneously to the
MDoS and MDiS regions (primarily localized at the C-termini
of PLA2-like toxins; Figs. 4 and 8). Suramin simultaneously
neutralizes the myotoxic and neuromuscular blocking activity
of MjTX-II when pre-incubated in vitro. Calorimetric data
demonstrated that suramin ligands bind to MjTX-II in the low
micromolar range, which corroborates the functional data.
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Figure 7
Average backbone r.m.s.d. during 50 ns molecular-dynamic simulations of
the tetrameric assembly of MjTX-II with (black) and without (grey)
suramin ligands. The simulations demonstrated that the bound assembly
(in black) presents a lower average r.m.s.d. value and a lower level of
r.m.s.d. fluctuations compared with the unbound assembly (grey).
Thus, the interaction of suramin with MjTX-II is in agreement
with the previous hypothesis for class (iii) inhibitors
(C-termini) but also reveals a broader class of inhibitor that is
able to bind to both the MDiS and MDoS regions. This is the
first report of a ligand that binds simultaneously to both sites
and explains its high efficiency as an inhibitor, as demon-
strated by functional and calorimetric assays.
In addition to suramin binding at the MDiS and MDoS
regions of MjTX-II, the oligomerization process observed for
the MjTX-II–suramin complex also strengthens the MDiS and
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Figure 8
MDoS (cationic membrane-docking site) and MDiS (hydrophobic membrane-disruption site) in the MjTX-II–suramin structure, highlighting the
interaction between the inhibitor and these sites. (a) Cartoon representation of the asymmetric unit of the crystal structure of the MjTX-II–suramin
complex with the inhibitor interacting with MDoS (residues in green) and MDiS (residues in red). Suramin and the MDoS and MDiS residues are shown
in ball-and-stick representation. (b) Detailed view of the interaction between a suramin molecule and a monomer of MjTX-II, highlighting the MDiS
(red) and MDoS (green) regions. The protein is represented as a surface and the suramin ligand is shown in ball-and-stick representation. (c) Tetrameric
conformation of the MjTX-II–suramin complex with the inhibitor interacting with the MDiS (red) and MDoS (green) regions.
MDoS burial process. Therefore, two synergic mechanisms can
potentially explain the demonstrated inhibition of MjTX-II by
suramin: (i) the suramin-binding mode on the toxin surface
that results in a blockade of both the MDoS and MDiS sites,
thus impairing toxin–membrane contacts (Figs. 8a and 8b),
and (ii) MjTX-II–suramin-induced oligomerization resulting
in a special protein–ligand quaternary arrangement that
makes the MDoS and MDiS of all of the oligomerized toxins
physically inaccessible (Fig. 8c).
4.4. Inhibitory mechanism of PLA2-like toxins
As shown in x3.6, in the crystal structure of the BaspTX-II–
suramin complex the suramin ligand interacts with the puta-
tive calcium-binding loop and C-terminal regions, obstructing
the hydrophobic channel (Murakami et al., 2005). By contrast,
in the crystal structure of the ecarpholin S–suramin complex
(Zhou et al., 2008) interactions of the ligand with the
C-terminal region were observed, particularly with Asn114,
Lys115 and Lys116 (this basic cluster has been proposed to be
part of the putative MDoS; Fernandes et al., 2014). Similarly,
suramin interacts with MjTX-II residues from the MDoS
(Lys115 and Lys116) and MDiS (Leu122 and Phe126). Thus,
despite the particularities of the interaction between suramin
and MjTX-II or ecarpholin S, there are some similarities in the
regions where the ligand binds to the toxins (MDoS region)
and in the oligomerization process undergone by the toxins
after ligand binding. These facts indicate that the inhibitory
processes of suramin towards both proteins are related.
In addition to suramin, rosmarinic acid also showed efficient
neutralizing characteristics for Lys49-PLA2s (Ticli et al., 2005;
dos Santos, Cardoso et al., 2011) and its complex has been
crystallographically characterized (dos Santos, Cardoso et al.,
2011). The authors of this study observed that rosmarinic acid
is bound at the entrance to the hydrophobic channel. There-
fore, based on the proposed myotoxic mechanism, dos Santos,
Cardoso et al. (2011) suggested that the inhibitory processes
occur because of ligand steric hindrance that blocks the access
of substrates to the hydrophobic channel.
Consequently, based on the effective inhibition by suramin
and rosmarinic acid, we propose two modes of inhibition of
PLA2-like proteins: (i) ligands binding in the hydrophobic
channel or blocking its access and (ii) ligands binding or
blocking access to the MDoS and MDiS regions. The first
inhibition mode avoids the binding of fatty acid to the toxin
that is necessary to activate the protein via an oligomeric
change, whereas the second mode avoids toxin docking and
membrane disruption. Because suramin and rosmarinic acid
act in both inhibitory processes, our experimental results are
promising for their potential use as drugs against the local
effects of myotoxic toxins.
5. Conclusions
In this study, we demonstrated that suramin is a potent inhi-
bitor that binds to MjTX-II with high affinity. The crystal
structure of the MjTX-II–suramin complex demonstrated for
the first time an inhibitor that binds simultaneously to the sites
of the toxin involved in membrane docking and disruption.
Furthermore, the crystal structure, DLS and MD simulations
identified the formation of higher-order oligomers (mainly
tetramers), which also aids in the inhibitory process. The
findings described in this work showed a great convergence
with the data in the literature and with mechanism of action of
PLA2-like toxins proposed by our group in recent years. Based
on these data, we suggest that suramin and other ligands (e.g.
rosmarinic acid) should be clinically studied as inhibitors of
the local myotoxic effects generated by PLA2-like proteins.
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